Drug Profile
Research programme: metabotropic glutamate receptor positive allosteric modulators - Domain Therapeutics
Alternative Names: DT 1687; DT 2208; DT2228; mGluR PAM - Domain Therapeutics; mGluR2 PAM; mGluR3 PAM; mGluR4 PAMsLatest Information Update: 28 Oct 2018
Price :
$50
*
At a glance
- Originator Faust Pharmaceuticals
- Developer Domain Therapeutics; Prexton Therapeutics
- Class Small molecules
- Mechanism of Action Metabotropic glutamate receptor 2 modulators; Metabotropic glutamate receptor 3 modulators; Metabotropic glutamate receptor 4 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Anxiety disorders; Parkinson's disease
- Discontinued Pain; Schizophrenia
Most Recent Events
- 28 Oct 2018 No recent reports of development identified for research development in Parkinson's-disease in France (PO)
- 22 Oct 2016 Research development is ongoing in Parkinson's disease in France (PO)
- 16 Jul 2016 No recent reports of development identified for research development in Anxiety-disorders in France (PO)